-
Novo Nordisk maintains outperform with $156 target By Investing.com
Источник: Buzz FX / 22 ноя 2024 14:06:16 America/Chicago
On Friday, BMO Capital maintained its positive stance on Novo Nordisk (NYSE: NVO ), reiterating an Outperform rating and a $156.00 price target for the pharmaceutical giant. The firm's analyst highlighted the anticipated benefits to Novo No
Read more...